Overview

To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer

Status:
Withdrawn

Trial end date:
2021-01-28

Target enrollment:

Participant gender:

Summary

A randomized, multi center, open label, two-period, single dose, crossover study to evaluate the bioavailability and safety of Paclitaxel Injection Concentrate for Suspension in Locally Recurrent or Metastatic Breast Cancer subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Sun Pharma Advanced Research Company Limited

Treatments:

Paclitaxel